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Accepted 26 January 2017; Published online 4 April 2017AbstractObjectives: The aim of this paper is to describe a conceptual framework for how to consider health equity in the Grading Recommen-
dations Assessment and Development Evidence (GRADE) guideline development process.
Study Design and Setting: Consensus-based guidance developed by the GRADE working group members and other methodologists.
Results: We developed consensus-based guidance to help address health equity when rating the certainty of synthesized evidence (i.e.,
quality of evidence). When health inequity is determined to be a concern by stakeholders, we propose five methods for explicitly assessing
health equity: (1) include health equity as an outcome; (2) consider patient-important outcomes relevant to health equity; (3) assess dif-
ferences in the relative effect size of the treatment; (4) assess differences in baseline risk and the differing impacts on absolute effects; and
(5) assess indirectness of evidence to disadvantaged populations and/or settings.
Conclusion: The most important priority for research on health inequity and guidelines is to identify and document examples where
health equity has been considered explicitly in guidelines. Although there is a weak scientific evidence base for assessing health equity, this
should not discourage the explicit consideration of how guidelines and recommendations affect the most vulnerable members of
society.  2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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Health inequities are differences in health that are not
only unnecessary and avoidable but are also considered
unfair and unjust [1]. As described in the introductory
paper in this series, we use the acronym PROGRESS Plus
(Place of residence, Race/ethnicity/culture/language,
Occupation, Gender/sex, Religion, Education, Socioeco-
nomic status, or Social capital þ personal, relational andtime-dependent characteristics) to identify individual
and context-specific characteristics across which health
inequities may occur [2].
Guideline panels need to decide early on whether they
plan to develop equity-sensitive recommendations (as
described in the introductory paper in this series). Using
explicit prompts may be helpful in this process [3]. In prin-
ciple, considering health equity is important for two main
types of guidelines: (1) universal interventions where health
nical Epidemiology 90 (2017) 76e83What is new?
Key findings
 This paper provides consensus-based guidance for
including health equity considerations in guideline
development.
What this study adds to what was known?
 This paper adds an equity framework to the
Grading Recommendations Assessment and Devel-
opment Evidence (GRADE) guidance for rating
the certainty of evidence in systematic reviews.
What is the implication and what should change
now?
 Considering health equity in rating the certainty in
synthesized evidence requires a priori elaboration
of the disadvantaged populations and settings of in-
terest, and methods to assess both relative and ab-
solute effects for these populations.
 GRADE judgements about directness require trans-
parent reporting of how judgements were made.
inequity is a concern [4e7]; and (2) targeted or dedicated
interventions aimed at one or more disadvantaged popula-
tions that have experienced health inequities. An example
of the latter is the Canadian immigrant health guidelines
[8], developed to raise awareness of migrant health needs
and improve access to effective preventive screening.
This paper provides guidance to address health equity
when rating the certainty in synthesized evidence using the
Grading Recommendations Assessment and Development
Evidence (GRADE) approach. This paper is the third paper
in a four-part series on health equity and GRADE, with the
introduction [Welch et al.], overall process [Akl et al.], and
evidence to decision methods [Pottie et al.].
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As discussed in the earlier two papers in this series,
several authors have assessed how guidelines consider
health inequity concerns [Welch et al. this series, Akl
et al. this series]. None of these papers focus on rating
the certainty of synthesized evidence (i.e., quality of
evidence) using the GRADE approach.3. GRADE certainty in synthesized evidence and
health equity
The GRADE approach of presenting the evidence by
outcome and the associated certainty (i.e., quality ofevidence) involves the production of summary tables.
These tables include evidence profiles (with details on the
rating of certainty for each outcome) and summary of
finding (SoF) tables that are intended for the public,
patients, purchasers, payers, practitioners, product makers
(e.g., manufacturers, industry), and policy makers [9].
Five methods can be used to assess health equity with
the GRADE approach:
a) Include health equity as an outcome
b) Consider patient-important outcomes relevant to
health equity
c) Assess differences in the magnitude of effect in relative
terms between disadvantaged and more advantaged
individuals or populations
d) Assess differences in baseline risk and hence the
differing impacts on absolute effects for disadvantaged
individuals or populations
e) Assess indirectness of evidence to disadvantaged
populations and/or settings.3.1. Consider including health equity as an outcome for
the SoF tables
If health inequity is considered an important concern by
relevant stakeholders, then health equity could be included
as an outcome in the Population, Intervention, Comparison,
Outcome questions, analytic framework, and SoF table. In
doing so, guideline developers must recognize that health
equity is primarily assessed with a subgroup analysis.
The developers should also note that this may risk
excluding other patient-important outcomes, if SoF tables
are limited to only seven outcomes as recommended by
GRADE. For example, the NICE guideline on maternal
and child nutrition identified impact on health inequalities
as one of its key priorities and framed its key question as:
‘‘What nutritional interventions are effective in improving
the health of preconceptual, pregnant, and postpartum
mothers and children (up to 5 years) and reducing
nutrition-related health inequalities’’ [10]. By including
health equity as an outcome in the SoF table, it is easier
for guideline panels to find the information (or lack
thereof) about health equity and consider it in their
deliberations.
The direction and size of the effect on health equity is
influenced by decisions such as the reference comparator
group, use of relative or absolute measures, and whether
the outcome is a desirable or undesirable event [11,12].
For example, the choice of absolute or relative effects can
change the conclusions about health inequalities. This is
illustrated by gender disparity in stomach cancer mortality
rates in the United States between 1930 and 2000 has
decreased when looking at absolute differences (the rates
for both men and women have declined). However, the rela-
tive risk for men compared to women has increased
(increased disparity, male/female ratio) [13].
Table 1. Effect of Community Water Fluoridation on socioeconomic health inequities in caries [14]
Outcome Measure Evidence
Health equity as measured by socioeconomic
disparities in caries
% of caries reduction Inconsistent results on socioeconomic
disparities (three studies)
dmft/DMFT No data on socioeconomic disparities
Abbreviation: DMFT/dmft, decayed, missing, or filled teeth.
Upper case refers to permanent teeth; lower case to primary teeth.
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outcome should not be a reason to omit this from the
SOF table. Indeed, this should be explicitly identified as
an empty row, highlighting the need for further research
to answer questions about health equity.3.1.1. Example 1
The Community Guide Water fluoridation guideline [14]
included ‘‘health disparities’’ as an outcome in the analytic
framework and the SoF table because the Community Task
Force placed a high value on reducing socioeconomic
disparities in dental caries. Socioeconomic disparities were
measured as the difference in absolute terms of a contin-
uous outcome (caries). The evidence review found three
studies that provided insufficient evidence about socioeco-
nomic disparities to draw conclusions, highlighting a gap in
the evidence base (Table 1).Table 2. Checklist for assessing credibility of subgroup analyses [22]
Design
Is the subgroup variable a characteristic measured at baseline or
after randomization?3.1.2. Example 2
‘‘Equity impact’’ was the primary outcome of a system-
atic review on interventions to reduce smoking in adults
[15]. Equity impact was assessed as the difference in the
magnitude of a dichotomous outcome in absolute terms,
defined as a difference in absolute effect on prevalence in
lower socioeconomic status compared to higher socioeco-
nomic status. This review showed that while increases in
price or taxes reduced health inequities in smoking, mass
media campaigns were more likely to worsen health
inequities. This type of review provides evidence that could
be used to include impact on health equity as an outcome of
interventions.Is the effect suggested by comparisons within rather than between
studies?
Was the hypothesis specified a priori?
Was the direction of the subgroup effect specified a priori?
Was the subgroup effect one of a small number of hypothesized
effects tested?
Analysis
Does the interaction test suggest a low likelihood that chance
explains the apparent subgroup effect?
Is the significant subgroup effect independent?
Context
Is the size of the subgroup effect large?
Is the interaction consistent across studies?
Is the interaction consistent across closely related outcomes within
the study?
Is there indirect evidence that supports the hypothesized interac-
tion (biological rationale)?3.2. Consider patient-important outcomes relevant to
health equity
As described in the previous paper in our series [Akl
et al. in this series], the evidence synthesis process should
consider the relative importance of different outcomes,
determined with input from stakeholders representing
disadvantaged groups. The evidence base for these out-
comes should then be assessed. Examples of patient impor-
tance and health equity were provided in the previous paper
in this series such as the importance of inconvenience of a
subcutaneous chelation pump for people with sickle cell
disease [described in Akl et al. in this series].3.3. Assess differences in the magnitude of effect in
relative terms between disadvantaged and more
advantaged individuals or populations
Average effects obscure differences between
subpopulationsdthat is, subgroup effects may exist. Exam-
ining whether effects differ across socioeconomic status or
other variables relating to health inequity requires investi-
gating heterogeneity in the treatment effectdfor example,
using statistical approaches such as meta-regression or sub-
group analysis. However, such results may not be available
in the literature. There is evidence that systematic reviews
underreport subgroup analyses from primary studies
[16,17]. Furthermore, many primary studies fail to assess
possible subgroup effects related to disadvantaged
populations.
Relative effects are usually similar across diverse popu-
lations and settings, and spurious subgroup effects are com-
mon [18]. Thus, if analysis suggests an apparent subgroup
effect, it is important to assess the credibility of the
apparent effect [19]. Sun and colleagues [20,21] describe
several criteria to help do this such as determining a priori
which subgroup analysis to conduct, finding a low P-value
associated with a statistical test for interaction, and
providing results from within-study comparisons. Sun
et al. also showed that subgroup analyses reported in the
literature rarely meet these criteria. Evidence synthesis that
involves subgroup analyses should therefore consider the
80 V.A. Welch et al. / Journal of Clinical Epidemiology 90 (2017) 76e83full set of credibility issues, using an appropriate checklist,
and avoid making conclusions based on chance findings
(Table 2).
If applying the criteria in Table 2 leads to a conclusion
that the subgroup effect is credible, the guideline panel
should provide different estimates of relative and absolute
effect for the subgroups. The panel should then consider
making different recommendations for patients in these
subgroups or consider whether recommendations that
apply to the overall population need to be adapted to
enhance equity. When the credibility of subgroup effects
is low, the guideline panel may suggest that further
research is needed. Few subgroup analyses meet all of
these criteria; however, when most criteria are met, deci-
sion making must consider the likely existence of sub-
group effects.3.3.1. Example: hypertension and ethnicity
The Eighth Joint National Committee guideline on man-
agement of hypertension recommends a calcium channel
blocker or thiazide-type diuretic as initial therapy in the
black hypertensive population (whereas an angiotensin-
converting enzyme inhibitor, angiotensin receptor blocker,
calcium channel blocker, or thiazide-type diuretic is recom-
mended for others with hypertension) [23]. This recom-
mendation was based on a prespecified subgroup analysis
of the ALLHAT trial (n 5 18,102 participants, 35% black
[24]) that showed stroke was 51% (95% CI: 1.22, 1.86)
greater for blacks treated with an ACE inhibitor first
compared to those treated with a calcium channel blocker.
The guideline panel rated this subgroup effect as moderate
quality evidence. Had the panel not identified this subgroup
effect, use of an ACE inhibitor as a first-line agent would
have increased health disparities between black and white
ethnic groups.3.4. Assess differences in baseline risk and the differing
impacts on absolute effects for disadvantaged
individuals or populations
A higher baseline risk of adverse events in any popula-
tion may lead to greater absolute harm from an intervention
and conversely a higher baseline prevalence of the outcome
of interest may lead to greater absolute benefit [25]. The
SoF table should present the baseline risks and risk differ-
ences for each relevant population and provide supporting
evidence. Because disadvantaged populations have a
disproportionate burden of almost all health conditions, it
is particularly important to consider the baseline risk for
these populations. Baseline risk of adverse event rates or
for the outcomes of interest for specific populations are best
assessed using the most robust observational data on the
actual population rather than from randomized trials.
GRADE guidance regarding assessing certainty of esti-
mates of risk from broad populations is available [26,27].3.4.1. Example 1: WHO guidelines on vitamin A
supplementation in children 6e59 months
In 2011, WHO recommended vitamin A supplementa-
tion for children aged 6 months to 5 years in countries
where vitamin A deficiency is a public health problem
(strong recommendation) [28]. This was based on findings
of a Cochrane review with a relative risk for all-cause
mortality of 0.76 (95% CI: 0.69, 0.83). The baseline risk
of all-cause mortality was estimated at 0/1,000 in low-
risk populations and 90/1,000 in high-risk populations
(with vitamin A deficiency), based on control group event
rates in the trials. Thus, the absolute effects in terms of
numbers of deaths prevented with vitamin A compared to
the control group were 0/1,000 for low-risk and 22/1,000
for high-risk populations.
3.4.2. Example 2: national guide to a preventive health
assessment for Aboriginal and Torres Strait Islander
people
In Australia, a guideline panel sought to determine the
optimal age at which to begin a series of preventive inter-
ventions in the Australian Aboriginal and Torres Strait
Islander population. The panel recommended preventive
interventions at an earlier age than the general population
on the basis of higher prevalence of preventable diseases
in Aboriginal and Torres Strait Islander populations. For
example, type II diabetes is 3e4 times more common than
in the general Australian population at all ages, leading to a
recommendation for screening starting from age 18, instead
of age 40 years for the general population [29].
3.5. Assess indirectness of evidence to disadvantaged
populations
GRADE quality (or certainty) ‘‘reflects our confidence
that the estimates of the effect are correct. In the context
of recommendations, quality reflects our confidence that
the effect estimates are adequate to support a particular
recommendation. ‘Quality’ as used in GRADE means more
than risk of bias and so may also be compromised by
imprecision, inconsistency, indirectness of study results,
and publication bias’’ [30]. Qualitative evidence may also
be important when considering health equity. Certainty
for qualitative evidence synthesis can be rated using the
CerQUAL tool [31] in which the domain ‘‘relevance’’ is
most closely aligned with directness.
Indirectness refers to the comparability between the pop-
ulation, the intervention, or the outcomes measured in
research studies and those under consideration in a guideline
or systematic review [32]. The GRADE approach evaluates
the lack of directness as ‘‘indirectness.’’ Direct evidence may
be lacking because some populations may not represent a
large proportion of trial populations (e.g., migrants and ref-
ugees), and data are unlikely to be disaggregated for specific
subgroups. Direct evidence may also be lacking because
some populations are explicitly excluded from trials, such
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[33e36]. Because multiple morbidities are more common
in socioeconomically disadvantaged people [37], this may
result in disproportionate exclusion of disadvantaged popula-
tions from trials. When direct evidence for the relevant
disadvantaged population is not available, guideline devel-
opers will have to evaluate the indirectness of evidence
obtained from other populations [38].
As a rule, certainty of the evidence should not be rated
down for indirectness for population differences unless there
are compelling reasons to anticipate differences in effect due
to biology/physiology, sociocultural influences, or setting-
specific resource issues that impact the effectiveness or
harms of the intervention. In other words, one anticipates
a different subgroup effect in either relative or absolute
impact of treatment, though evidence is not available to
make a formal assessment. (If it were, it should be formally
assessed, as in Sections 3.3 and 3.4) Guideline panels need
to consider that rating down for indirectness could in itself
increase inequities if this leads to less use of an effective
intervention by disadvantaged groups. In other words, lower
certainty in effect estimates may lead to a weak recommen-
dation and therefore under-use of a beneficial treatment.
Rating down for indirectness should therefore be done
cautiously because effective interventions are needed even
more in some populations that are often excluded from trials,
such as those with multiple morbidities.
3.5.1. Example 1: Canadian migrant guidelines not
rated down for indirectness
The quality of the evidence was not rated down for indi-
rectness in the Canadian migrant guideline addressing
screening for latent TB; the panel considered the evidence
not to be indirect for migrants. Although no migrants were
included in studies of intervention effectiveness, the devel-
opers did not expect different relative effects [39].
3.5.2. Example 2: CDC guidelines for brief alcohol
counseling for people with HCV infection rated down
for indirectness
The Centers for Disease Control and Prevention recom-
mended brief alcohol screening and counseling for all
person with HCV infection, based on a systematic review
of 22 randomized trials which found a reduction of alcohol
consumption of 38.42% (95% CI: 30.91, 65.44) more than
the control groups after 1 year. This evidence was rated
down for indirectness by the guideline panel because none
of the trials included persons with hepatitis C virus (HCV)
infection [40].4. Methodologic challenges
In developing this guidance, we identified a number of
methodologic challenges. First, assessing effects on health
equity is not a linear process. There may be a need to revisitthe focus of the guideline during the evidence review
process, including the consideration of important disadvan-
taged groups. NICE does this explicitly by revisiting their
key questions regarding health equity throughout the process.
Second, there are often limitations in the underlying
evidence base including poor reporting of sociodemo-
graphic characteristics [41,42], under-reporting of subgroup
analyses that are not statistically significant [21,42], and use
of multivariable models that may be overadjusted for effect
mediators, and/or include unnecessary collinear variables
[43]. Lack of evidence on whether the effects are consistent
or different for disadvantaged populations makes it difficult
to judge indirectness and rate certainty of evidence. When
the evidence base is insufficient to assess effects on health
equity, guideline panels need to make these limitations
explicit and transparently report how they made judgments.
Third, epidemiologic evidence addressing baseline risk
for specific disadvantaged groups may be difficult to obtain
for the population or geographic region for which the
recommendations are being developed. Health systems at
local, regional, and national levels do not have consistent
or reliable methods for reporting health status across all
sociodemographic indicators of interest. Guideline panels
should transparently report how they determined baseline
risk estimates.
Fourth, assessing directness of evidence depends on the
clinical and methodological expertise and judgment of SoF
developers. The GRADE Guideline Development Tool
includes an explicit checklist when producing SoFs to ask
whether the evidence is direct across population, interven-
tion, comparison, and outcome and document the decision
for rating down, if performed.5. Research agenda
The most important research priority in the field of
health equity and guidelines is to systematically identify
further examples of how guideline panels have assessed
health equity considerations and incorporated these assess-
ments into recommendations using transparent methods.
For example, all WHO guidelines make their evidence to
recommendation tables and SoFs publicly available for
research such as this. These assessments could provide
examples of whether, and how, the five issues (aee) above
have been considered for different situations, such as
assessing the credibility of subgroup analyses and judging
indirectness for disadvantaged populations.
In conclusion, the GRADE process provides a structured
approach to assess effects on health equity. Health equity
considerations warrant increased use of these methods in
systematic reviews and guidelines. The findings of assess-
ing health equity using these five steps in guideline devel-
opment provides a basis for judging ‘‘impact on equity’’
which is part of the DECIDE framework, and details about
this process are covered in the fourth paper of this series
[Pottie et al.].
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